Document Detail

Novel approaches to Behçet's disease.
MedLine Citation:
PMID:  11060788     Owner:  NLM     Status:  MEDLINE    
Behçet's disease is a systemic inflammatory disorder. The patients have repeated exacerbations and remissions of the symptoms. This disease may produce a wide variety of symptoms. In mild cases, mucocutaneous lesions are only the symptoms during the whole clinical course, whereas ocular lesions, which occur in about 70% of the patients, can cause blindness. Involvement of the gastrointestinal tract, CNS and large vessels is less frequent, but sometimes life-threatening. Colchicine, NSAIDs, corticosteroids and immunosuppressants are employed for the treatment of Behçet's disease with therapies tailored to individual patients depending on clinical manifestations. Cyclosporin A is the most effective drug for ocular lesions at the present, but its neurotoxicity, which occurs in 20-30% of patients receiving cyclosporin A, restricts usage of the agent. Many patients are still suffering from a severe form of uveitis and serious neurological symptoms, which are resistant to any conventional therapies. New drugs have been investigated for Behçet's disease. IFN-alpha therapy has shown significant efficacy for common symptoms including ocular lesions without any serious adverse effects. Thalidomide and its analogues also appear to be applicable to this disease. Monoclonal antibody to TNF-alpha is now in clinical trials. These novel therapeutic approaches may provide much needed treatment options for patients with Behçet's disease.
T Sakane; M Takeno
Related Documents :
6789728 - Hemagglutination tests for tuberculosis with mycobacterial glycolipid antigens. results...
7322498 - Delayed hypersensitivity to thimerosal in soft contact lens wearers.
3521558 - Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease.
6770888 - Genetic markers in glaucoma.
21732998 - External validation of exhaled breath profiling using an electronic nose in the discrim...
21778058 - Clinical characteristics and predictive factors of myasthenic crisis after thymectomy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  9     ISSN:  1354-3784     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2000-12-11     Completed Date:  2000-12-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1993-2005     Citation Subset:  IM    
Department of Immunology and Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Behcet Syndrome / diagnosis,  drug therapy*,  physiopathology
Cyclosporine / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Interferon-alpha / therapeutic use*
Thalidomide / therapeutic use*
Reg. No./Substance:
0/Antiviral Agents; 0/Immunosuppressive Agents; 0/Interferon-alpha; 50-35-1/Thalidomide; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic developments in peroxisome biogenesis disorders.
Next Document:  Sjögren's syndrome: current therapies remain inadequate for a common disease.